Roche To Work On Reversing English Funding Rejection For SMA Drug

But Tecentriq Gets NICE Thumbs Up For NSCLC

Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.

Pile of British money pounds sterling new one pound coins GBP in four piles close-up with NHS above. Rising cost of National Health Service concept UK — Roche needs to offer a price for Evrysdi that is cost-effective for the NHS • Source: Alamy

Roche has pledged to work to reverse NICE’s preliminary decision this week that its spinal muscular atrophy (SMA) treatment, Evrysdi (risdiplam), should not be made available to patients on England’s National Health Service because it is too expensive.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Roche To Work On Reversing English Funding Rejection For SMA Drug

But Tecentriq Gets NICE Thumbs Up For NSCLC

Read the full article – start your free trial today!

More from United Kingdom

More from Europe